Severe Eosinophilic Asthma: Key Decisions That Drive Effective Strategies with Targeted Therapies

Enter asthma patient characteristics in this online CCO tool and compare your treatment plan with those of 5 experts.

Michael E. Wechsler, MD, MMSc
Program Director Bradley E. Chipps, MDFAAP, FACAAI, FAAAAI, FCCP Nicola Alexander Hanania, MD, MS Linda Rogers, MD Eileen Wang, MD, MPH Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Released: August 5, 2020 Expired: August 4, 2021

Expert commentaries detailing why determining endotype is crucial to managing severe asthma and how targeted biologic therapies have advanced treatment for type 2 asthma.

Eileen Wang, MD, MPH Michael E. Wechsler, MD, MMSc Physicians: maximum of 0.5 AMA PRA Category 1 Credits™ Released: October 7, 2020 Expired: October 6, 2021

Why determining endotype is crucial to managing severe asthma.

Michael E. Wechsler, MD, MMSc Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Released: August 24, 2020 Expired: August 23, 2021

Here’s why targeted biologic therapies are a great advance for treating type 2 asthma.

Eileen Wang, MD, MPH Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Released: September 21, 2020 Expired: September 20, 2021